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Background: Sub-Sahara Africa hosts up to 71 % of all HIV infected people in the world. With this high incidence
of Human immunodeficiency virus ( HIV) comes the burden of co-morbidities such as malignant and premalignant
lesions. Aids defining malignancies have been listed as Kaposi’s sarcoma, Non-Hodgkin’s lymphoma and invasive
squamous cell carcinoma of the cervix. People with HIV/AIDS(PLWAS) have a higher risk of developing these
neoplasms than the rest of the population. The pathogenesis of these neoplasms in people with HIV has been
linked to immune suppression, persistent antigenic stimulation and cytokine dysregulation.
Current study analyzes and presents the patterns and trends in the presentation of HIV related malignancies in
patients diagnosed through histopathology at Kenyatta National Hospital.
Aim: To describe the patterns of AIDS- defining and non-AIDS- defining malignancies and premalignant lesions
10 years pre- and post HAART period at Kenyatta National hospital, Kenya.
Methods and techniques: This was a hospital based descriptive cross sectional study. The Formalin fixed paraffin
embedded (FFPE) blocks and histological reports of patients diagnosed between 2000 and 2011 were traced from
archives. The patients’ demographic data and clinical presentation was entered in an excel spreadsheet and the
diagnosis and coding confirmed by a histopathologist. The data was then cleaned and analyzed using SSPS
version 17.0 Ink.
Results: A total of 173 lesions were reviewed and analyzed. Of these 118 (68 %) were from females and 55 from
males (32 %). The male to female ratio was 1:2. The age range was from two to 56 years with a median of 36 years.
Kaposi sarcoma is the leading AIDS defining malignancy in Kenya while invasive squamous cell carcinoma of the
conjunctiva is the leading non-AIDS defining malignancy. This is closely followed by invasive squamous cell
carcinoma of the cervix and NHL.
Conclusion: Kaposi sarcoma is the leading AIDS associated neoplasm in Kenya. Physicians and caretakers
managing and following up on HIV/AIDS patients should look out for Kaposi sarcoma as a form of IRIS following
the institution of HAART in all HIV/AIDS patients. The incidence of invasive squamous cell carcinoma of the
conjunctiva is increasing in PLWAS in Kenya. There is therefore a need to introduce early screening programs for
squamous intraepithelial neoplasm of the conjunctiva in HIV/AIDS patients.* Correspondence: rogena.emily@gmail.com
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Sub-Saharan Africa hosts up to 71 % of all adults and
children living with HIV, 70 % of adults and children
newly infected, and 75 % of adults and children dying
from AIDS [1]. In Kenya 1.6million people were living
with HIV, with a prevalence rate of 6.1 % in adults 15–
49 years of age, and death due to AIDS of 57,000 in
2012 [1]. With this high incidence and prevalence of
HIV comes the burden of co-morbidities such as malig-
nant and premalignant lesions [2]. AIDS defining
malignancies have been listed as Kaposi sarcoma, Non-
Hodgkin’s lymphoma and invasive squamous cell carcin-
oma of the cervix [3, 4]. People with HIV/AIDS have a
higher risk of developing these neoplasms than the nor-
mal population [3]. The pathogenic mechanisms of these
neoplasms are still not well understood although several
authors suggest immune suppression, persistent anti-
genic stimulation, and elevated pro-inflammatory cyto-
kines and other viruses as cofactors. [2]. Some of the
cytokines that have been associated with these cancers
include vascular endothelial growth fact VEGF, Kaposi’s
sarcoma growth factor KSGF, IL-6, and HIV Tat protein
and IFgamma and alpha [5, 6]. These cytokines and fac-
tors influence the cell cycle and hence proliferation via
several mechanisms that will not be discussed in this art-
icle. Although the sub-Saharan Africa leads in the inci-
dence of HIV/AIDS, data on trends of AIDS associated
malignancies in African countries is scanty [7–9]. This is
partly attributed to the lack of well-established cancer
registries [7–11], as is the case in Kenya. Most of the
data in literature emanates from Uganda, possibly due to
the presence of an active Kampala cancer registry which
has been in existence since 1954 [12]. Literature from
the developed countries show that following the intro-
duction of HAART, the incidence of KS was significantly
reduced amongst HIV/AIDS patients [2]. In addition the
incidence of other neoplasms that are not AIDS defining
have increased in these patients [2]. There has been an in-
crease in the incidence of other neoplasms also referred to
as non-AIDS defining neoplasm such as Hodgkin’s lymph-
oma, myeloma, hepatocellular carcinoma and gastric
adenocarcinoma [2]. It is against this background that we
set out to review the trend of HIV related malignancies
seen at our department of Pathology between 2000 to
2011. In this study we describe the patterns of AIDS- de-
fining and non-AIDS- defining malignancies and prema-
lignant lesions 11 years pre- and post HAART period at
Kenyatta National hospital Kenya (Table 1).
Methods and techniques
Having obtained approval from the KNH/UON ethics
and research committee. The data clerk at the AIDS and
Cancer Specimen Resource-Kenya (ACSR K) retrieved
all the reports indicated to be HIV positive on thehistological request forms between 2000 and 2011. This
was done by checking for clinical information on the
form indicating p24 marker positive (p24 is a marker of
HIV antigenicity in serum), retroviral disease, if patient
was on ARV or HAART treatment, or patient on follow-
up at the comprehensive care clinic (CCC). Using the
histological reports, blocks for the respective cases were
then retrieved from the routine block storage and ar-
chived. 4 The criteria for inclusion as HIV positive case
included information from the clinician in the patient’s
histological request form indicating follow up at the
CCC, HAART treatment, ARV treatment, immunosup-
pression, p24 marker reactive, retrovirus disease, and
HIV positive.
The patients’ demographic and clinical data from the
histological request form and partly from the hospital
medical records were entered into Microsoft Excel 2010.
Ink spreadsheet. The data was cleaned and analyzed
using SPSS statistics 17.0 Ink.
Results
A total of 173 lesions were reviewed and analyzed by the
study histopathologists (Ndungu, JR, Rogena, EA). Of
these 118 (68 %) were females and 55 males (32 %). The
male to female ratio was 1:2. The age range was from 2
to 56 years with a median of 36 years (Fig. 1). Between
the year 2000 and 2003, the main neoplasm reported
was Kaposi’s sarcoma and squamous cell carcinoma.
Starting from 2003, other neoplasms such as High grade
Non-Hodgkin’s lymphoma and gastric adenocarcinoma
began to emerge. Kaposi’s sarcoma represents the largest
number of cases at 48 % followed by squamous cell
carcinoma of the conjunctiva and cervix/vulva at 12.5 %
and 5.6 % respectively. Aggressive Non-Hodgkin’s
lymphoma account for 4.6 %; of these lymphomas and
Burkitt lymphoma make up 0.6 %. The premalignant le-
sion, carcinoma-in-situ (CIS),is seen both in the cervix
and the conjunctiva. However, squamous cell carcinoma
is more prevalent in the conjunctiva (Fig. 2). In our sam-
ple the aggressive non-Hodgkin’s lymphomas are found
in the less common sites such as the appendix and the
skin. The only Burkitt lymphoma reported was in an
adult, involving the appendix. Kaposi’s sarcoma is also
seen frequently in the appendix and the oropharynx. Of
interest is the lack of ano-rectal carcinoma in this series
(Figs. 3 and 4).
Discussion
The male to female ratio of 1:2 reported to have AIDS
Related malignancies is in keeping with the higher inci-
dence of HIV infection in the female population in
Kenya as shown by the National HIV indicators for
Kenya 2010 (National HIV Indicators for Kenya: 2010
National AIDS Control Council and the National AIDS























Skin 35 1 0 0 2 0 0 0 0 38
Cervix/Vulva 0 0 10 0 0 0 20 0 0 0 30
Orbit/Eye/
Conjunctiva
0 3 22 0 0 0 8 0 0 0 33
Appendix 1 15 1 0 1 5 0 0 0 1 24
Stomach/
Gastric
0 0 1 1 0 0 0 0 0 0 2
Uterus 0 0 1 0 0 0 5 0 0 0 6
Breast 0 0 0 0 0 0 0 1 0 0 1
Bone/Soft
tissue
0 0 2 1 0 0 0 0 0 0 3
Tongue/Oral
cavity/gingival




0 15 0 0 0 0 0 0 0 0 15
Liver 0 0 0 0 0 0 0 0 1 0 1




1 82 173 173 173 173 173 173 173 173 173
Rogena et al. Infectious Agents and Cancer  (2015) 10:28 Page 3 of 7and STD Control Program). The female gender is at a
higher risk of acquiring HIV infection due to many fac-
tors such as the anatomy and the immunity of the repro-
ductive system and socio-economic factors [1, 11]. Over
the years Kaposi sarcoma, squamous cell carcinoma of
the uterine cervix and High Grade Non-Hodgkin’sFig. 1 Distribution of the cases by sex. The Pie chart shows the
distribution of males and females in the study. There were 68.2 %
female and 32.8 % malelymphomas have been listed as AIDS defining malignan-
cies. The AIDS defining malignancies are neoplasms that
consistently correlate with the presence of AIDS in HIV
infected persons. In a pilot study by Korir et al. in
Kenya, the authors observed that of 171 cases, 118 had
tumors associated with HIV, including Kaposi’s sarcoma,
cervical cancer, non- Hodgkin’s lymphoma, Hodgkin’s
disease, and conjunctival carcinoma [11]. The non-AIDS
defining malignancies appear to occur at much younger
age in HIV infected persons compared to those that are
HIV negative, the neoplasms show atypical features, and
a higher grade and stage at the time of diagnosis [12].
The data in this study reveals a progressive increase in
the number and variety of malignancies and premalig-
nant lesions diagnosed since the introduction of HAART
in 2003. The trend is such that Kaposi’s sarcoma and
squamous cell carcinoma of the cervix and vulva pre-
dominated between 2000 and 2003, the pre HAART
period in Kenya. Kaposi’s sarcoma is still leading, but in-
cidence of squamous cell carcinoma of the conjunctiva
is surpassing that of the cervix and vulva. Later in 2003,
majority of HIV patients started receiving ARV from
MEDS (Mission for essential drug suppliers- a catholic
church NGO). Following this, in the same year, the
Kenya government announced the inception of HAART
treatment through public hospitals which were imple-
mented through funding by GLOBAL and PEPFAR
funds in 2004 [15]. Over the period of eight years, up to
Fig. 2 The distribution of types of Lesions by age. The figure shows the distribution of cancers by age of diagnosis in HIV-1 cases in Kenyatta
National Hospital between 2001 and 2011
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pects an increase in the survival of people living with
HIV/AIDS. The developed countries over the years have
recorded a significant decrease in the incidence of AIDS
related malignancies since the introduction of HAART
in those settings [16]. In Kenya, the trend appears to
demonstrate a relative increase in the number of cases
and the variety of AIDS related malignancies. This could
be accounted for by the survival rate of these patients as
the HAART programs become widespread. Another fac-
tor that may contribute to the high incidence is the en-
demicity of KSHV (HHV8) in East Africa. In this study
we did not actively review the information on the correl-
ation of HAART use and the neoplasm. Nor did weFig. 3 The distribution of neoplasms Reported between 2000 and 2011. Th
2001–2011 using patient charts and FFPEcorrelate the KSHV marker, LANA 1 marker and the
presence of Kaposi’s sarcoma as objectives of the study.
Reports from Kampala, Uganda show that HIV related
Kaposi’s sarcoma affects mainly the younger and middle
age groups, and the median age in 1990s being 32.0 years
and 27.1 years for men and women respectively. This
distribution is similar to the median age of AIDS cases
recorded for the country in 1996 of 34 years and 30 years
in men and women respectively [12]. KS can involve any
site in HIV infected persons, including bone marrow,
pancreas, gastrointestinal tract (GIT), lungs, liver, heart,
and testis [17]. The oral cavity, palate and larynx are
other common sites. Of the 82 cases of Kaposi’s sarcoma
reported in this study (42.7 %) showed involvement ofe figure shows the cancers identified in Kenyatta National Hospital in
Fig. 4 The distribution of neoplasms by site. The figure shows specific types of neoplasms detected at Kenyatta National Hospital with respect
to site
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represented 15 % each, and the conjunctiva and tongue/
oral mucosa was at 3.7 % and 17.1 % respectively. Kaposi’s
Sarcoma associated with HIV is said to be more aggressive
and has been shown to occur at these unusual sites [12].
This observation has led to the proposal that HIV-1
encoded proteins such as Tat protein may induce some
cytokines that work synergistically with products of
HHV8 [16, 18, 19]. Tat interacts with RB2/P130 tumor
suppressor gene among other pathways [20]. KS may
flare up upon introduction of HAART in some cases.
This is thought to be due to Immune reconstitution
syndrome, a reaction to some of the infections seen in
HIV [21]. Due to the scanty nature of the clinical infor-
mation accompanying histological specimens to the la-
boratory, one would not easily elucidate this syndrome
using laboratory data. Recent studies from Kenya,
Uganda and South Africa show that HAART is effective
in reducing the standardized incidence of KS [22].
Invasive squamous cell carcinoma of the cervix is clas-
sified as one of AIDS defining malignancies. The occur-
rence of this neoplasm in HIV represents a progression
to AIDS. The neoplasm is directly linked to HPV, a virus
that has been shown to transform squamous cells
through the E6 and E7 proteins. These proteins act viathe cyclin dependent kinases E/CDK2 to phosphorylate
and inactivate RB gene. Proposals have been put forth
suggesting that HIV may upregulate E6 and E7 through
Tat [23]. Whereas the pathogenesis of squamous cell
carcinoma of the conjunctiva and that of the cervix is
similar, the study shows that invasive squamous cell car-
cinoma of the conjunctiva has surpassed that of the
uterine cervix. On the other hand CIS is more prevalent
in the uterine cervix than in the conjunctiva. This re-
versed trend could be as result of the cervical screening
programs in Kenya, targeting all women. However, there
is no such program targeting the conjunctiva in PLWAs
in Kenya. A review of HIV related cancers in Uganda re-
vealed a dramatic increase in invasive squamous cell car-
cinoma of the conjunctiva from four cases reported
between1960 to 1971 and 66 cases reported between
1994 and 1997 [12]. Similarly, Ateenyi from Uganda
demonstrated similar positive correlation between squa-
mous cell carcinoma of the conjunctiva and HIV in 1995
[24]. Although cancer of the cervix is classified as AIDS
defining, Uganda series do not show a significant risk
between HIV positive and HIV negative women. How-
ever, the Ugandan reports reveal a significant link be-
tween CIS and HIV infection [16]. Nonetheless, lesions
diagnosed through screening programs have to be
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biases introduced by screening programs that lead to the
diagnosis of these premalignant lesions such as CIS.
In general aggressive B cell lymphomas are one of the
nightmares in management of HIV/AIDS. These neo-
plasms are usually non-responsive to routine protocols.
Diffuse large B cell lymphomas form the largest percent-
age followed by Burkitt lymphoma. Non Hodgkin’s
lymphoma put together accounted for 4.6 % of all the
neoplasms and premalignant lesions in this study. In the
United States, the relative risk of NHL in subjects with
AIDS is 100 or more and much higher than the relative
risk in an African series reporting that shows Rwanda
leads at 13 [95 % confidence interval (CI), 2.2–44.4] [25]
and South Africa at 4.8 (95 % CI, 1.5–14.8) [26]. The risk
of developing lymphoma steadily increases with duration
of HIV infection and advancing immunosuppression.
Prospects for increased survival are enhanced by HAART;
however, long-term survivors of HIV infection may re-
main at increased risk for NHL [27]. The slow roll out
of HAART use may partly account for death of HIV/
AIDS patients earlier in this setting prior to the diagno-
sis of lymphomas hence the low reported incidence in
this study.
Burkitt lymphoma in sub-Saharan Africa is mainly a
childhood disease accounting for up to 82 % of all
pediatric and adolescent lymphomas in the region [28].
HIV related BL however occurs mainly in adults as
shown in this study and presents at unusual sites. All
the cases of Burkitt lymphomas in the HIV/AIDS pa-
tients were reported between the ages of 51 to 60 years.
The numbers given in this study may be an underesti-
mation since the main diagnostic method for Burkitt
lymphoma has been Fine needle aspiration Cytology
(FNAC). Therefore histological records would understate
the incidence.
Recent data reported from several hospitals in East
Africa reveal that Hodgkin’s Lymphoma is a disease of
children and adolescents [28], the only case of Hodgkin’s
lymphoma in this review was reported between the age
of 31 to 40 years. The disease has been reported to be
on the increase in HIV/AIDS [16]. There appears to be a
linkage between EBV and HIV in the pathogenesis of
lymphomas, a fact that calls for further research. Nearly
all HLs are associated with EBV [23]. The EBV related
proteins EBNA 1, EBNA 2, EBNA-LP, EBNA 3A and
EBNA-3C and LMP differentially drive the cells through
notch pathway, cell cycle check point (G2/M) and by ac-
tivation of NF-κB [29]. We would like to point out that
a number of the cases diagnosed in the period may not
have been retrieved due to challenges in record keeping.
Although Burkitt lymphoma is one of the well re-
ported high grade lymphomas seen in HIV/AIDS, the
cases reported in this study were very few. Of note isthat during the period under review, the main diagnostic
method for Burkitt lymphoma was largely through
FNAC, and may account for the low incidence of ar-
chived tissue of BL in this series.
Conclusion
Kaposi sarcoma is the leading AIDS associated neoplasm
in Kenya. The incidence of invasive squamous cell carcin-
oma of the conjunctiva is increasing in PLWAS in Kenya.
There is therefore a need to introduce early screening
programs for squamous intraepithelial neoplasm of the
conjunctiva in HIV/AIDS patients.
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